在资产重组时，对目标资产精准估值是发掘长期价值的关键。纵观成功案例，上市公司深度考量目标企业的核心技术、市 场前景与盈利潜力，并据此制定科学的估值方案，方能实现资源的最优配置，为未来发展注入强劲动力。上市公司应综合运用 市场法、收益法、成本法等，多维度审视标的，还可引入独立第三方专业估值机构，借助其经验与专业视角，确保评估客观公 正，精准捕捉目标资产的价值。 ■肖伟 今年以来，上市公司资产重组热度高涨。据Wind资讯统计，今年上半年共有1493家A股上市公司披露1984单并购重组计 划，其中构成重大资产重组的有102单，同比增长121.74%。 笔者认为，上市公司在推进重组的过程中，需在资产估值、风险控制、内部整合三个核心环节精准把控，稳健运作，如此 方能积蓄长远发展动能。 其一，精准评估相关资产估值，锚定增长路径。 其三，整合重在融合，释放协同效能。 资产重组绝非简单的叠加，而是要追求"1+1>2"的深度协同。整合成功与否，要看是否实现了业务高效协同、管理优化升 级、文化深度融合。上市公司欲实现科学整合，必须果断舍弃低效业务、精简重叠产品线，大力培育新增长点。同时，上市公 司也应建立健全高效灵活的管理与沟通 ...

内蒙古蒙电华能热电股份有限公司董事会 关于评估机构的独立性、评估假设前提的合理性、评估方 法与评估目的的相关性以及本次交易定价公允性的说明 内蒙古蒙电华能热电股份有限公司（以下简称"公司"或"内蒙华电"）拟 通过发行股份及支付现金方式购买北方联合电力有限责任公司分别持有的北方 上都正蓝旗新能源有限责任公司 70%股权与北方多伦新能源有限责任公司 "本次交易"）。 为完成本次交易，公司聘请了北京中企华资产评估有限责任公司（以下简 称"中企华评估"）作为评估机构，对本次发行股份及支付现金购买的标的资产 的价值进行评估。 中企华评估为本次交易出具的相关资产评估报告的评估假设前提按照国家 有关法律法规执行，遵循了市场通行惯例或准则，符合评估对象的实际情况， 评估假设前提具有合理性。 三、评估方法与评估目的的相关性 本次评估的目的是确定标的资产于评估基准日的价值，为本次重组提供价 值参考依据，中企华评估实际评估的资产范围与委托评估的资产范围一致。本 次资产评估工作按照国家有关法规与行业规范的要求，中企华评估在评估过程 中实施了相应的评估程序，遵循了独立性、客观性、科学性、公正性等原则， 运用了合规且符合标的资产实际情况 ...

Group 1 - The independent financial advisor, Guotai Junan Securities Co., Ltd., has been appointed by Inner Mongolia Mengdian Huaneng Thermal Power Co., Ltd. to provide advisory services for the acquisition of assets through share issuance and cash payment, along with raising supporting funds [1] - The independent financial advisor conducted due diligence and internal verification in accordance with relevant laws and regulations, ensuring that the professional opinions expressed align with the disclosed documents of the listed company [1] - The advisor confirmed that the restructuring plan complies with legal and regulatory requirements, and that the disclosed information is true, accurate, and complete, without any false records or significant omissions [1] Group 2 - Strict confidentiality measures and risk control protocols are in place to prevent insider trading, market manipulation, and securities fraud [1]

国泰海通证券股份有限公司（以下简称"国泰海通证券"、 国泰海通证券股份有限公司 关于本次交易相关主体不存在不得参与任何上市公司重大资产重组 情形的核查意见 内蒙古蒙电华能热电股份有限公司（以下简称"公司"）拟发行股份及支付 现金购买北方联合电力有限责任公司持有的北方上都正蓝旗新能源有限责任公 司 70%股权与北方多伦新能源有限责任公司 75.51%股权，并向不超过 35 名特定 投资者发行股份募集配套资金（以下简称"本次交易"）。 （以下无正文） （本页无正文，为《国泰海通证券股份有限公司关于本次交易相关主体不存在不 得参与任何上市公司重大资产重组情形的核查意见》之签章页） 财务顾问主办人： 王 靓 张 维 国泰海通证券股份有限公司 "独立财务顾问"） 作为本次交易的独立财务顾问，就本次交易相关主体是否存在依据《上市公司监 管指引第 7 号——上市公司重大资产重组相关股票异常交易监管》第十二条或 《上海证券交易所上市公司自律监管指引第 6 号——重大资产重组》第三十条不 得参与任何上市公司重大资产重组的情形进行核查并发表如下意见： 本次交易涉及的《上市公司监管指引第 7 号——上市公司重大资产重组相关 股票异 ...

证券代码：600863 证券简称：内蒙华电 公告编号：临 2025-037 债券代码：240363 债券简称：23 蒙电 Y1 债券代码：240364 债券简称：23 蒙电 Y2 内蒙古蒙电华能热电股份有限公司 关于股东权益变动的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 本次权益变动系内蒙古蒙电华能热电股份有限公司（以下简称 "公司"） 发行股份及支付现金购买资产并募集配套资金之发行股份购买资产导致交易对 方北方联合电力有限责任公司（以下简称"北方公司"）新增持有公司股份（以 下简称"本次权益变动"），未触及要约收购。 ? 本次权益变动后，北方公司及其一致行动人合计持有公司 4,301,373,112 股股份，占公司股份总数的 58.49%。 ? 本次权益变动不会导致公司控股股东及实际控制人变更，不会对公司日 常生产经营产生重大影响。 一、本次权益变动的基本情况 公司拟通过发行股份及支付现金相结合的方式向北方公司购买其持有的北 方上都正蓝旗新能源有限责任公司 70%股权与北方多伦新能源有限 ...

智元机器人的资本首秀来了。 7月9日，上纬新材（688585.SH）宣布上海智元新创技术有限公司（下称"智元机器人"）控制的主体上海智元恒岳科技合伙企业（有限合伙）（下 称"智元恒岳"）、及关联方上海致远新创科技设备合伙企业（有限合伙）（下称"致远新创"）将至少收购其63.62%股份，交易作价不低于19.96亿 元。 交易完成后，上纬新材的控股股东、实控人将双双变更为智元恒岳、邓泰华。 若该交易达成，上纬新材将成为科创板首家人形机器人企业旗下公司。 市场的期待显然不仅于此，更受关注的，莫过于改朝换代的上纬新材能否成为智元机器人未来的上市平台，进而跻身A股市场"人形机器人第一 股"。 虽然智元机器人强调最近12个月内并未有向上纬新材注入资产的计划。 但市场依旧反应激烈，当日上纬新材开盘一字涨停。 从实操来看，智元机器人若想以上纬新材为主体上市确实不是易事。 目前智元机器人的估值是上纬新材的数倍，短期内注入资产大概率构成借壳上市，这在科创板中未有先例； 但这并不意味着智元机器人会就此罢手。 在现行规则下，其仍然可通过36个月后重组或将资产"分步走"等方式来规避"借壳上市"认定审查，但届时机器人行业是否依旧保持高景 ...

Core Viewpoint - MicuBio (688321.SH) announced the final top-line analysis data from its pivotal Phase III clinical trial (DEB study) for its self-developed drug, Sidanbamide, which significantly outperformed the control group in terms of event-free survival (EFS), achieving the primary endpoint of the study [2][4] Group 1: Product and Market Information - Sidanbamide is the world's first subtype-selective histone deacetylase (HDAC) inhibitor and belongs to the class of epigenetic regulators [4] - The drug received conditional approval for DLBCL indications from the National Medical Products Administration (NMPA) in April 2024 and is set to be included in the national medical insurance catalog by the end of 2024, making it the only oral innovative drug for first-line DLBCL within the insurance coverage [4] - DLBCL is the most common type of lymphoma in China, with approximately 60,000 to 80,000 new cases reported annually, and the incidence rate is gradually increasing [4] Group 2: Clinical Trial and Regulatory Information - The company previously received conditional approval based on interim analysis data, requiring completion of clinical trials within two years to obtain complete clinical data [4] - The announcement of the final results signifies an expansion of the existing indication range for the product, positively impacting the company [4] - Conditional approval allows for accelerated market entry of urgently needed drugs with significant clinical value, even before completing full clinical research [5] Group 3: Competitive Landscape - The treatment field for DLBCL has seen recent breakthroughs, including the approval of Tafasitamab, a CD19 monoclonal antibody for relapsed/refractory DLBCL, which does not directly compete with Sidanbamide as it is used for second-line or later treatments [5] Group 4: Financial Performance - The company reported a revenue of 658 million yuan for 2024, a year-on-year increase of 25.63%, but faced a net loss of 115 million yuan, a significant decline of 228.97% [6] - In the first quarter of 2025, revenue was 162 million yuan, up 24.24% year-on-year, but the net loss was 19 million yuan, a decrease of 4.64% compared to the previous year [6]

Core Viewpoint - The Hong Kong Stock Exchange (HKEX) is experiencing a significant surge in IPO activities, with multiple companies successfully listing and attracting substantial investments, indicating a revitalized market confidence and a robust pipeline for future listings [2][7][10]. Group 1: Recent IPO Activities - On July 9, five companies including Lens Technology and Geek+ collectively listed on the HKEX, creating a lively atmosphere and showcasing the exchange's appeal [2][4]. - Lens Technology, with a market capitalization exceeding 110 billion HKD, completed its IPO in just 100 days, marking a record speed for the HKEX [4]. - Geek+, a robotics unicorn, achieved a market valuation of 22 billion HKD upon listing, highlighting the growing interest in technology-driven companies [4][5]. Group 2: Market Trends and Statistics - Over 40 companies successfully completed IPOs on the HKEX in the first half of the year, raising a total of 1,067 billion HKD, a dramatic increase of 688.56% compared to the previous year [7]. - Notable IPOs include CATL, which reached a market value of 1.3 trillion HKD, and other major players like Heng Rui Medicine and Hai Tian Flavor, each raising over 10 billion HKD [7]. - The HKEX is preparing for over 100 upcoming IPOs, with around 200 applications currently received, indicating a strong pipeline for future listings [7][10]. Group 3: Investor Sentiment and Market Dynamics - There is a renewed confidence in the HKEX, with institutional investors actively seeking opportunities to list companies, contrasting sharply with previous years' challenges [10][11]. - In the first half of the year, 36 out of 42 listed companies had cornerstone investors, accounting for 43.7% of total IPO fundraising, demonstrating strong backing from major investment firms [10]. - The successful performance of cornerstone investors in recent listings has further fueled interest in the HKEX as a viable platform for capital raising [11].

Core Viewpoint - The legal opinions and reports provided by Shanghai Tongli Law Firm regarding Anhui Jianghuai Automobile Group Co., Ltd.'s issuance of A-shares to specific targets in 2024 indicate that the company has addressed compliance issues related to its management structure and external investments, ensuring that its independence is maintained despite previous irregularities [1][2][11]. Group 1: Legal Opinions and Compliance - The law firm has issued multiple legal opinions and reports concerning the company's A-share issuance, including supplementary legal opinions addressing inquiries from the Shanghai Stock Exchange [1][2]. - The company has rectified issues related to its executives holding labor contracts with the controlling shareholder, Jiangqi Holdings, ensuring compliance with the latest corporate governance standards [4][11]. - The company has established a robust internal control system, which has been confirmed by external auditors, ensuring effective execution of its governance and compliance measures [9][11]. Group 2: Management Structure and Independence - The company's executives, including the general manager and deputy general manager, hold board positions at Jiangqi Holdings but do not occupy other administrative roles, which aligns with the revised corporate governance guidelines [4][11]. - The labor contracts previously held with Jiangqi Holdings have been transferred to the company, and salaries are now paid by the company, mitigating any potential conflicts of interest [4][11]. - The company has implemented a strict personnel management system, ensuring that its management operates independently from its controlling shareholder [6][8]. Group 3: Overseas Investment Compliance - Some overseas subsidiaries of the company have not obtained the necessary investment project filings, primarily due to misunderstandings of regulatory requirements, but these issues are being actively rectified [20][21]. - The company has confirmed that the overseas subsidiaries' operations do not pose significant risks to its overall business, as their financial contributions are minimal [16][20]. - The company has taken corrective actions for its overseas subsidiaries, ensuring compliance with investment regulations and minimizing the risk of project suspension by regulatory authorities [19][20].

Group 1: Investment Trends in Embodied Intelligence - The investment frenzy in the embodied intelligence sector has reached a boiling point, with four companies announcing new funding rounds totaling nearly 2.6 billion RMB, with individual amounts exceeding 1 billion RMB [1] - In the first five months of 2025, there were 114 investment events in China's embodied intelligence sector, with total financing exceeding 23 billion RMB, surpassing the total for the entire previous year [1] Group 2: Strategic Acquisition by Zhiyuan Robotics - Zhiyuan Robotics announced a strategic acquisition of over 63% controlling stake in Upwind New Materials for approximately 2.1 billion RMB, causing a significant market reaction [2][4] - The acquisition was structured in two steps: an agreement to acquire 29.99% of shares and a partial tender offer to increase ownership to 66.99% [5][6] Group 3: Implications of the Acquisition - The acquisition allows Zhiyuan Robotics to bypass traditional IPO routes, simplifying the approval process and providing a direct channel to public capital markets [6][15] - This move offers early investors an exit strategy, enhancing their confidence in Zhiyuan's future prospects [16] - The acquisition paves the way for future industry integration and operational flexibility, allowing Zhiyuan to leverage its position for further growth [17] Group 4: Company Background and Leadership - Zhiyuan Robotics is led by co-founder and CTO Peng Zhihui, known for his innovative projects, while Deng Taihua, a former Huawei executive, plays a crucial role in the company's strategic direction [8][12] - The company has rapidly developed a range of robotic products and platforms, showcasing its ambition to become a foundational technology provider in the robotics sector [12][14] Group 5: Market Dynamics and Future Outlook - The robotics industry is transitioning from a focus on physical capabilities to the integration of advanced AI models, with Zhiyuan's GO-1 model positioned as a key player in this shift [14] - The current market demands practical applications of robotics in real-world environments, making Zhiyuan's acquisition a strategic move to accelerate its maturity and commercial viability [14][19]